One-Stop care: hepatitis c treatment may curb HIV and opioid risks

NCT ID NCT03221309

Completed Disease control Sponsor: University of Maryland, Baltimore Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new way to care for people who inject drugs and have hepatitis C. Along with standard hepatitis C treatment, participants were offered HIV prevention medication and buprenorphine for opioid use disorder. The goal was to see if this combined approach could cure hepatitis C, reduce HIV risk, and support recovery. The study enrolled 198 adults with ongoing injection drug use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BUPRENORPHINE are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection posterior leukoencephalopathy syndrome HIV infectious disease prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

BUPRENORPHINE HCV PREP

Contacts and locations

Locations

HIPS

Washington D.C., District of Columbia, 20002, United States
University of Maryland Drug Treatment Center

Batlimore, Maryland, 21223, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.